CLCA4

Across TCGA pan-cancer cohorts, CLCA4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLCA4 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CLCA4 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CLCA4 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, UCEC, and LIHC are the cancer types where CLCA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	1.000	0.397	.002	36	view →
UCEC	DFS	Median	All	0.979	0.824	.004	26	view →
LIHC	DFS	Median	All	0.123	0.547	<.001	15	view →
HNSC	OS	Median	IV	0.183	0.641	.006	12	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLCA4–BLCA (OS)

Open the BLCA breakdown →